U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07846033) titled 'A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities' on Sept. 09.
Brief Summary: This is a Phase 1, randomized, double-blind, placebo-controlled single ascending dose (SAD) study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of VK3019 in overweight and obese adults without comorbidities.
Study Start Date: July 06
Study Type: INTERVENTIONAL
Condition:
Obese Adults
Intervention:
DRUG: SC VK3019
Single dose VK3019
DRUG: Matching placebo
Single dose matching placebo
Recruitment Status: RECRUITING
Sponsor: Viking Therapeutics, Inc.
Published by HT Digital Content Servi...